PD-16 Atezolizumab plus bevacizumab is associated with improved survival outcomes in HCC patients with Child-Pugh B dysfunction compared to best supportive therapy
| Autor: | Fulgenzi, C., D'Alessio, A., Scheiner, B., Ang, C., Wietharn, B., Pinter, M., Nishida, N., Parisi, A., Huang, Y., Bettinger, D., Vogel, A., Silletta, M., Schönlein, M., Galle, P., Kudo, M., Singal, A., Cortellini, A., Chon, H., Stefanini, B., Giannini, E., Pinato, D. |
|---|---|
| Zdroj: | In Annals of Oncology June 2023 34 Supplement 1:S7-S7 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|